Nasdaq btai.

Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ...NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Follow. NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BTAI support price is $3.53 and resistance is $4.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI stock will trade within this expected range on the day. View a ...

Fintel reports that on October 5, 2023, Truist Securities downgraded their outlook for BioXcel Therapeutics (NASDAQ:BTAI) from Buy to Hold . Analyst Price Forecast Suggests 650.57% Upside As of ...

Isaac Mitchell. November 25, 2023. Technologies. BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $4.00, to imply an increase of 4.44% or $0.17 in intraday trading. The BTAI share’s 52-week high ...BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.NASDAQ: BTAI ® BXCL701 Key Opinion Leader Day February 21, 2023 ... | April 10, 2023

NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...

BioXcel Therapeutics ( NASDAQ: BTAI ), based in Connecticut, develops treatments for CNS and cancer disorders, including FDA-approved Igalmi (marketed sublingual dexmedetomidine) and BXCL701 for ...

BioXcel Therapeutics will host a conference call and webcast at 8:30 a.m. ET on March 9 to discuss its fourth quarter and full-year 2022 financial results and provide an update on recent ...Net Loss: BioXcel Therapeutics reported a net loss of $26.8 million for the third quarter of 2021, compared to a net loss of $24.8 million for the same period in 2020. As of September 30, 2021 ...NEW HAVEN, Conn., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing ...Sign In. Market Data; /; Stocks; /; BTAI; /; Advanced Chart. BioXcel Therapeutics Inc. U.S.: Nasdaq. Watchlist. 0.00. BTAI. Real Time Quote. Open. $3.8600.Aug 14, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...

BioXcel Therapeutics (NASDAQ:BTAI) announces that the FDA has accepted for filing the New Drug Application (NDA) for BXCL501, an investigational, orally dissolving thin film formulation of ...Shares of BioXcel Therapeutics ( BTAI -1.80%) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501 ...This forecast implies upside of 128%. Thus, BTAI could be one of the best short-squeeze stocks. Aravive (ARAV) Source: Epic Cure / Shutterstock. Hailing from Houston, Texas, Aravive (NASDAQ:ARAV) ...Price. %Change. 3.830. -1.79%. paper trading platform. Webull offers BTAI Ent Holdg (BTAI) historical stock prices, in-depth market analysis, NASDAQ: BTAI real-time stock quote data, in-depth charts, free BTAI options chain data, and a fully built financial calendar to help you invest smart. Buy BTAI stock at Webull.NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET... NEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI ...

(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 118.87% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.69%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.54%.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.42 million.SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...NEW HAVEN, Conn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BTAI DEADLINE: ROSEN, ... (NASDAQ: BTAI) between... BTAI: 3.93 (+2.61%) BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options PR Newswire - Sat Sep 2, 6:00AM CDT ...NEW HAVEN, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ... Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ...Find the latest SEC Filings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.NEW HAVEN, Conn., May 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BioXcel Therapeutics ( BTAI 2.61%) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...

A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM

Oct 10, 2023 · Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ... 25 May 2023 ... Healthcare Stocks on the Move Thursday: ELEV, CDIO, HSCS, XBIT, ANNX, BIOC, BTAI, BHG · These Healthcare stocks are trading higher: · These ...BTAI - Stock Quotes for BTAI Ent Holdg, NASDAQ: BTAI Stock Options Chain, Prices and News - Webull MARKET BTAI BTAI Bioxcel Therapeutics Inc NASDAQ 3.772 -0.028 …Aug 16, 2022 · The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ... BioXcel Therapeutics Inc (NASDAQ:BTAI) showed a performance of 51.72% in past 30-days. Number of shares sold short was 5.81 million shares which calculate 1 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $10.50 to the stock, which implies a rise of 58.1% to its current value.View Your Watchlist. Stock analysis for Bioxcel Therapeutics Inc (BTAI:NASDAQ CM) including stock price, stock chart, company news, key statistics, …More specifically, Citadel Investment Group was the largest shareholder of BioXcel Therapeutics, Inc. (NASDAQ:BTAI), with a stake worth $32.5 million reported as of the end of September.Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ...A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.25%.Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ...

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...Nov 14, 2023 · On November 14, 2023, BioXcel Therapeutics Inc ( NASDAQ:BTAI) released its 8-K filing, announcing strategic advancements and financial results for the third quarter ended September 30, 2023. The ... BioXcel Therapeutics (NASDAQ:BTAI), a biopharma company based in Connecticut, leverages AI and machine learning to develop innovative treatments for central nervous system and immuno-oncology ...Instagram:https://instagram. sectors in share marketfinancial advisors philadelphiawayfair stock forecastrebel stock Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023. 10 cent stock4 weeks handyman courses BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ... exc dividend BioXcel Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BTAI updated stock price target summary.BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...